drugset / Trial / NCT01600612
Oxytocin, Carbetocin and Misopristol for Treatment of Postpartum Hemorrhage: A Multicentric Randomized Trial
RandomizedParallel-groupOpen-labelTreatment
Summary
Postpartum hemorrhage (PPH) is the leading cause of maternal death worldwide, with an estimated mortality of 140 000 per year. Uterine atony is one of the most important causes of PPH. The traditional treatment of which is the use of uterotonic agents. Oxytocin is the most conventional drug which was proved effective. However, it has the shortcomings of short half life and the necessity of intravenous administration. Misopristol, and more recently Carbetocin were introduced for treatment of atonic PPP not responding to Oxytocin. Aim of the study is to evaluate the effectiveness of Carbetocin, Misopristol, and Oxytocin for treatment of atonic PPH.
Timeline
- Start
- 2012-09
- Primary completion
- 2013-06
- Completion
- 2013-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Carbetocin | Peptide | 10 ug | Intravenous |
| Comparator | Misoprostol | Other / unclassified | 600 ug | Other |
| Comparator | Oxytocin | Peptide | 30 iu | Intravenous |
Indications
No indication recorded.